Form 8-K United Health Products, For: Jul 07

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL

6. SNDK
7. TAP
8. DELL
9. ROIV
10. HUBS

Top News Most Read Special Reports

July 10, 2026 12:19 PM EDT

E-mail

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2026

UNITED HEALTH PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-27781

84-1517723

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

320 Boston Post Road, Suite 180

Darien, CT 06820

(Address of Principal Executive Offices) (Zip Code)

(475) 755-1005

Registrant’s telephone number, including area code

520 Fellowship Road, Suite #D-406

Mt. Laurel, NJ 08054

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 7, 2026, United Health Products, Inc. issued a press release announcing an agreement with NAMSA, an established global MedTech contract research organization, whereby NAMSA will serve as regulatory sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze in connection with our FDA Premarket Approval (PMA) application.

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

We refer you to the risk factors in Part I, “Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of the risks relating to our Premarket Approval application.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description

99.1		Press release, July 7, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.